Executives On The Move: Clinical VPs Exit Eisai And Pfizer And New Top Hire At Histogen
Clinical VPs exit Eisai and Pfizer for positions at mRNA product firm CureVac and nanomedicines developer Taiwan Liposome. New chairman and CEO takes the reins at regenerative medicine company Histogen.
You may also be interested in...
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.
Coronavirus Update: AstraZeneca’s Vaccine Trials Cleared To Restart In the US, J&J Prepares To Restart Its Vaccine Study
Two potential COVID-19 vaccine trials from AstraZeneca and Johnson & Johnson are set to resume in the US following temporary pauses due to safety concerns. Data from both could come later this year.
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.